Genomic Valley Biotech share news, announcements and annual reports
BSE: 539206Pharmaceuticals & BiotechnologySmall Cap
Share price at the BSE close on 30 Oct 2026. Previous close ₹45.81.
30 Oct: open ₹48.10, high ₹48.10, low ₹48.00
- Under BSE's graded surveillance, stage I, on the list for 29 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹15 Cr4,774th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 3.74
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- −0.1%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 0.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.00
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 9,359
Genomic Valley Biotech share news and announcements
492 announcements, routine notices left out, newest first. Page 2 of 10.
Feb 2025
10 Feb · Board meeting
Meeting on 14 Feb 2025: quarterly results
Jan 2025
8 Jan · Management
Dec 2024
6 Dec · Corporate action
2 Dec · Board meeting
Meeting on 6 Dec 2024
Oct 2024
3 Oct · Board meeting
Meeting on 7 Oct 2024: quarterly results
Sep 2024
6 Sep · Board meeting
Aug 2024
Jul 2024
23 Jul · Board meeting
Meeting on 29 Jul 2024: quarterly results
May 2024
9 May · Non-Applicability Of Regulation 23(9) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
9 May · Results
9 May · Board meeting
3 May · Board meeting
Meeting on 9 May 2024: audited results
Apr 2024
30 Apr · Compliance Certificate Under Reg 40(10) Of LODR Reg.
30 Apr · Compliance Certificate Under Reg. 7(3) Of LODR Reg, 2015
Feb 2024
14 Feb · Management
14 Feb · Management
14 Feb · Announcement under Regulation 30 (LODR)-Change in Corporate Office Address
14 Feb · Results
12 Feb · Board meeting
Meeting on 14 Feb 2024: quarterly results
Dec 2023
14 Dec · Management
Nov 2023
14 Nov · Management
14 Nov · Management